# Kevin Li

> Kevin Li is a Series C investor at Frazier Life Sciences backing Biopharma. See 3 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Frazier Life Sciences](https://shizune.co/investors/profile/frazier-life-sciences)
- Location: Palo Alto, United States
- Total investments: 3
- Last investment: Feb 2026
- Lead investor: 100%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/kvinli/

Kevin Li is a Series C investor at Frazier Life Sciences in Palo Alto focused on Biopharma and Biotechnology. Kevin Li is based out of Westlake Village, California and is the Partner of Frazier Life Sciences and Board of Director of Angitia Biopharmaceuticals. Kevin Li attended Yale University.

## Contacts

5 contacts available for Kevin Li: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/kevin-li-58cc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 33% |
| Series D | 1 | 33% |
| Post-IPO Equity | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 33% |
| Canada | 1 | 33% |
| Sweden | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $130M | Series D | Feb 05, 2026 | https://angitiabio.com/ |
| 35Pharma | 35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need. | $53M | Series C | Nov 26, 2024 | https://35pharma.com |
| Egetis Therapeutics | Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development. | $15.8M | Post-IPO Equity | Oct 10, 2023 | https://www.egetis.com/ |

3 of 3 investments shown.

## Co-investors
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 2 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 2 deals together
- [3H Health Investment](https://shizune.co/investors/profile/3h-health-investment) — VC Fund, 1 deal together
- [Columbia Threadneedle Investments](https://shizune.co/investors/profile/columbia-threadneedle-investments) — VC Fund, 1 deal together
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 1 deal together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 1 deal together

## About Frazier Life Sciences

VC Fund · Seattle, United States

Frazier Life Sciences IX is a venture capital fund. Frazier Life Sciences invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to public.

1 contacts available at Frazier Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Tao Fu | Venture Partner | https://shizune.co/investors/profile/tao-fu |

## Similar investors

### Similar stage
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund

## FAQ

### What does Kevin Li invest in?

Kevin Li invests primarily in Biopharma, Biotechnology and Medical startups, most often at Series C and Series D stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kevin Li?

Public channels for Kevin Li include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Kevin Li last invest?

The most recent investment recorded for Kevin Li closed in Feb 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co